Funds · 13F holdings

Elmind Capital, LP

13F holdings for Q2 2026 · NEW YORK, NY · filed August 14, 2026

Elmind Capital, LP reported $398M in 13F securities across 35 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were COGT (11.4%), SNDX (10.2%), CLDX (9.3%). Reported value rose 13.0% from the quarter before. It opened 6 new positions, added to 9, trimmed 6 and sold out of 5.

13F value Q2 2026
$398M
Holdings
35
Change vs prior quarter
+13.0%
Rank by 13F value
#4,469

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Top holdings

StockValueWeightSharesChange in sharesMove
COGT Cogent Biosciences Inc.$45.3M11.4%1,170,7400%Unchanged
SNDX Syndax Pharmaceuticals Inc.$40.6M10.2%1,855,0000%Unchanged
CLDX Celldex Therapeutics Inc.$36.8M9.3%990,000+14.5%Added
RLAY Relay Therapeutics Inc.$27.4M6.9%1,465,279+172.9%Added
PCVX Vaxcyte Inc.$26.3M6.6%452,340+42.9%Added
VERA Vera Therapeutics Inc.$18.7M4.7%436,518-9.5%Trimmed
Pharvaris NV$18.2M4.6%525,750+10.5%Added
VRDN Viridian Therapeutics Inc.$18.1M4.5%984,931+84.1%Added
CTMX CytomX Therapeutics Inc.$17.1M4.3%4,550,0000%Unchanged
TVTX Travere Therapeutics Inc.$16.6M4.2%292,600+64.8%Added
LEGN Legend Biotech Corporation$16.5M4.1%570,569NewNew
BEAM Beam Therapeutics Inc.$16.3M4.1%476,3380%Unchanged
CGEM Cullinan Therapeutics Inc.$12.6M3.2%690,000+30.2%Added
NRIX Nurix Therapeutics Inc.$11.2M2.8%460,0000%Unchanged
KRYS Krystal Biotech Inc.$8.2M2.1%22,0000%Unchanged
UTHR United Therapeutics Corporation$8.1M2.0%15,0000%Unchanged
SMMT Summit Therapeutics Inc.$7.2M1.8%493,820NewNew
INSM Insmed Incorporated$6.9M1.7%65,000NewNew
BCRX BioCryst Pharmaceuticals Inc.$5.2M1.3%520,000-48.0%Trimmed
MBX MBX Biosciences Inc.$5.0M1.3%91,000-56.9%Trimmed
PTGX Protagonist Therapeutics Inc.$4.7M1.2%38,0000%Unchanged
Urogen Pharma LTD$4.4M1.1%120,000-45.5%Trimmed
DBVT DBV Technologies S.A.$4.3M1.1%265,0000%Unchanged
ALMS Alumis Inc.$3.7M0.9%130,0000%Unchanged
Supernus Pharmaceuticals$3.3M0.8%70,000+250.0%Added

Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $398M in share positions; options and bonds count in the 13F value but not here.

Biggest buys in Q2 2026

  1. RLAY Relay Therapeutics Inc. Added+$17.4M
  2. LEGN Legend Biotech Corporation New+$16.5M
  3. VRDN Viridian Therapeutics Inc. Added+$8.3M
  4. PCVX Vaxcyte Inc. Added+$7.9M
  5. SMMT Summit Therapeutics Inc. New+$7.2M
  6. INSM Insmed Incorporated New+$6.9M
  7. TVTX Travere Therapeutics Inc. Added+$6.5M
  8. CLDX Celldex Therapeutics Inc. Added+$4.7M
  9. CGEM Cullinan Therapeutics Inc. Added+$2.9M
  10. Supernus Pharmaceuticals Added+$2.3M

Biggest sells in Q2 2026

  1. Kalvista Pharmaceuticals Inc Sold out-$20.6M
  2. CGON CG Oncology Inc. Sold out-$19.7M
  3. TYRA Tyra Biosciences Inc. Trimmed-$10.5M
  4. MBX MBX Biosciences Inc. Trimmed-$6.6M
  5. BCRX BioCryst Pharmaceuticals Inc. Trimmed-$4.8M
  6. Urogen Pharma LTD Trimmed-$3.7M
  7. Apellis Pharmaceuticals Inc Sold out-$2.0M
  8. VERA Vera Therapeutics Inc. Trimmed-$2.0M
  9. DSGN Design Therapeutics Inc. Trimmed-$1.4M
  10. enGene Holdings Inc. Sold out-$1.4M

The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 6 new, 9 added, 6 trimmed, 5 sold out.

Sector mix

13F value by quarter

Q4 '25
Q1 '26
Q2 '26
Reported 13F value: Q4 2025 $339M, Q1 2026 $352M, Q2 2026 $398M.

More holdings

StockValueWeightSharesChange in sharesMove
BMRN BioMarin Pharmaceutical Inc.$2.7M0.7%47,0000%Unchanged
IMCR Immunocore Holdings plc$2.6M0.6%81,143+39.3%Added
AMLX Amylyx Pharmaceuticals Inc.$2.0M0.5%112,0000%Unchanged
ALEC Alector Inc.$1.8M0.5%900,0000%Unchanged
SEPN Septerna Inc.$1.7M0.4%49,444NewNew
DSGN Design Therapeutics Inc.$1.6M0.4%107,900-48.1%Trimmed
STRO Sutro Biopharma Inc.$1.1M0.3%32,037NewNew
Wave Life Sciences LTD SHS$1.0M0.3%177,8460%Unchanged
TYRA Tyra Biosciences Inc.$639K0.2%20,000-94.3%Trimmed
ENGN enGene Therapeutics Inc.$363K0.1%210,000NewNew

Questions about Elmind Capital, LP

What does Elmind Capital, LP own?
In its Form 13F for Q2 2026, Elmind Capital, LP reported 35 holdings worth $398M. The five largest were COGT, SNDX, CLDX, RLAY, PCVX.
What did Elmind Capital, LP buy and sell in Q2 2026?
Elmind Capital, LP opened 6 new positions, added to 9, trimmed 6 and sold out of 5 compared with the quarter before.
When did Elmind Capital, LP file its latest 13F?
Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.

From Form 13F filed by Elmind Capital, LP (SEC CIK 0002052213) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON